Live-attenuated CHIKV vaccine VLA1553

BIOLOGICAL4 trials

Sponsors

Valneva Austria GmbH

Conditions

Chikungunya Virus Infection

Unknown Phase

Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Active, not recruitingNCT07163845

Valneva Austria GmbHChikungunya Virus Infection

Start: 2025-09-22End: 2026-12-31Updated: 2026-02-11

Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Active, not recruitingNCT07254702

Valneva Austria GmbHChikungunya Virus Infection

Start: 2026-02-02End: 2027-02-28Target: 5000Updated: 2026-07-21

Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil

Enrolling by invitationNCT07347002

Valneva Austria GmbHChikungunya Virus Infection

Start: 2026-02-02End: 2027-12-31Target: 1200Updated: 2026-07-17

VLA1553-403 Pregnancy Surveillance Study

Enrolling by invitationNCT07414524

Valneva Austria GmbHChikungunya Virus Infection

Start: 2026-06-11End: 2027-12-31Target: 200Updated: 2026-07-20